Literature DB >> 15814878

Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia.

Hiroki Yamaguchi1, Rodrigo T Calado, Hinh Ly, Sachiko Kajigaya, Gabriela M Baerlocher, Stephen J Chanock, Peter M Lansdorp, Neal S Young.   

Abstract

BACKGROUND: Mutations in TERC, the gene for the RNA component of telomerase, cause short telomeres in congenital aplastic anemia and in some cases of apparently acquired hematopoietic failure. We investigated whether mutations in genes for other components of telomerase also occur in aplastic anemia.
METHODS: We screened blood or marrow cells from 124 patients with apparently acquired aplastic anemia and 282 control subjects for sequence variations in the TERT, DKC1, NHP2, and NOP10 genes; an additional 81 patients and 246 controls were examined for genetic variations in TERT. Telomere lengths and the telomerase activity of peripheral-blood leukocytes were evaluated in patients carrying genetic variants. Identified mutations were transfected into telomerase-deficient cell lines to examine their effects and their mechanism of action on telomerase function.
RESULTS: Five heterozygous, nonsynonymous mutations (which cause an amino acid change in the corresponding protein) were identified in TERT, the gene for the telomerase reverse transcriptase catalytic enzyme, among seven unrelated patients. Leukocytes from these patients had short telomeres and low telomerase enzymatic activity. In three of these patients, the mutation was also detected in buccal mucosa cells. Family members carrying the mutations also had short telomeres and reduced telomerase activity but no evident hematologic abnormality. The results of coexpression of wild-type TERT and TERT with aplastic anemia-associated mutations in a telomerase-deficient cell line suggested that haploinsufficiency was the mechanism of telomere shortening due to TERT mutations.
CONCLUSIONS: Heterozygous mutations in the TERT gene impair telomerase activity by haploinsufficiency and may be risk factors for marrow failure. Copyright 2005 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15814878     DOI: 10.1056/NEJMoa042980

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  280 in total

1.  Short telomeres, telomeropathy, and subclinical extrapulmonary organ damage in patients with interstitial lung disease.

Authors:  Gautam George; Ivan O Rosas; Ye Cui; Caitlin McKane; Gary M Hunninghake; Phillip C Camp; Benjamin A Raby; Hilary J Goldberg; Souheil El-Chemaly
Journal:  Chest       Date:  2015-06       Impact factor: 9.410

2.  Telomere length in myelodysplastic syndromes.

Authors:  Dana E Rollison; P K Epling-Burnette; Jong Y Park; Ji-Hyun Lee; Hyun Park; Kristen Jonathan; Ashley L Cole; Jeffrey S Painter; Mayenha Guerrier; Johana Meléndez-Santiago; William Fulp; Rami Komrokji; Jeffrey Lancet; Alan F List
Journal:  Leuk Lymphoma       Date:  2011-06-03

Review 3.  Telomerase and idiopathic pulmonary fibrosis.

Authors:  Mary Armanios
Journal:  Mutat Res       Date:  2011-11-04       Impact factor: 2.433

4.  Inherited bone marrow failure syndromes.

Authors:  Inderjeet Dokal; Tom Vulliamy
Journal:  Haematologica       Date:  2010-08       Impact factor: 9.941

Review 5.  Prospects and challenges of building a cancer vaccine targeting telomerase.

Authors:  Robert H Vonderheide
Journal:  Biochimie       Date:  2007-07-17       Impact factor: 4.079

6.  No attenuation of the ATM-dependent DNA damage response in murine telomerase-deficient cells.

Authors:  Natalie Erdmann; Lea A Harrington
Journal:  DNA Repair (Amst)       Date:  2008-12-25

7.  Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.

Authors:  Edward D Esplin; Ling Oei; Michael P Snyder
Journal:  Pharmacogenomics       Date:  2014-11       Impact factor: 2.533

8.  Peripheral blood lymphocyte telomere length as a predictor of response to immunosuppressive therapy in childhood aplastic anemia.

Authors:  Hirotoshi Sakaguchi; Nobuhiro Nishio; Asahito Hama; Nozomu Kawashima; Xinan Wang; Atsushi Narita; Sayoko Doisaki; Yinyan Xu; Hideki Muramatsu; Nao Yoshida; Yoshiyuki Takahashi; Kazuko Kudo; Hiroshi Moritake; Kazuhiro Nakamura; Ryoji Kobayashi; Etsuro Ito; Hiromasa Yabe; Shouichi Ohga; Akira Ohara; Seiji Kojima
Journal:  Haematologica       Date:  2014-05-09       Impact factor: 9.941

Review 9.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

Review 10.  Principles of adoptive T cell cancer therapy.

Authors:  Carl H June
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.